← Back to screener

Artiva Biotherapeutics, Inc. ARTV

Rank #2164 · Nasdaq · $0.1B market cap
Audited by KPMG LLP, no going-concern flag in the latest filing.
Score
31.1
P/E
-1.6
P/B
-0.64
ROE
40.3%
Op. Margin
-26805.6%
Debt Ratio
-14%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Poor

P/E -1.6x, P/B -0.64x. Ranks in the top 99% of the universe.

Profitability ★★☆☆☆
Average

ROE 40.3%. Ranks in the top 55% of the universe.

Safety ★★★★★
Excellent

Debt ratio -14%. Ranks in the top 7% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 99.3% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2024$0.0B$-0.0B$-0.0B$-0.1B-91.6-36
2025$0.0B$-0.1B$-0.1B$-0.2B-26805.6-14

← See the full screener